stage-specific expansion and harbor genetic and epigenetic alterations Stem and progenitor cells in myelodysplastic syndromes show aberrant

Steidl and Amit Verma Silverman, Jaroslaw Maciejewski, John M. Greally, B. Hilda Ye, Alan F. List, Christian Steidl, Ulrich Parekh, Christine McMahon, Andrea Pellagatti, Jacqueline Boultwood, Cristina Montagna, Lewis Yu, Tushar D. Bhagat, Sanchari Bhattacharyya, Laura Barreyro, Christoph Heuck, Yonkai Mo, Samir Britta Will, Li Zhou, Thomas O. Vogler, Susanna Ben-Neriah, Carolina Schinke, Roni Tamari, Yiting stage-specific expansion and harbor genetic and epigenetic alterations Stem and progenitor cells in myelodysplastic syndromes show aberrant

[1]  A. Feinberg,et al.  Regulated Noise in the Epigenetic Landscape of Development and Disease , 2012, Cell.

[2]  M. J. Ruiz,et al.  Stat3 signaling in acute myeloid leukemia: ligand-dependent and -independent activation and induction of apoptosis by a novel small-molecule Stat3 inhibitor. , 2011, Blood.

[3]  E. Estey,et al.  Coalesced multicentric analysis of 2,351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the international prognostic scoring system. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Hua Yu,et al.  STAT3 inhibition is a therapeutic strategy for ABC-like diffuse large B-cell lymphoma. , 2011, Cancer research.

[5]  P. Vyas,et al.  Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia. , 2011, Cancer cell.

[6]  S. Orkin,et al.  Dnmt3a silences hematopoietic stem cell self-renewal , 2011, Nature Genetics.

[7]  P. Woll,et al.  Persistent malignant stem cells in del(5q) myelodysplasia in remission. , 2010, The New England journal of medicine.

[8]  S. Orkin,et al.  DNA methylation in adult stem cells: New insights into self-renewal , 2010, Epigenetics.

[9]  M Cazzola,et al.  Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells , 2010, Leukemia.

[10]  M. Kawahara,et al.  Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome. , 2009, Blood.

[11]  Lucy Skrabanek,et al.  MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. , 2009, Blood.

[12]  S. Orkin,et al.  DNA methyltransferase 1 is essential for and uniquely regulates hematopoietic stem and progenitor cells. , 2009, Cell stem cell.

[13]  Reid F. Thompson,et al.  High-resolution genome-wide cytosine methylation profiling with simultaneous copy number analysis and optimization for limited cell numbers , 2009, Nucleic acids research.

[14]  Valeria Santini,et al.  Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. , 2009, The Lancet. Oncology.

[15]  C. O'keefe,et al.  Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. , 2009, Blood.

[16]  J. McNamara.  Cancer Stem Cells , 2007, Methods in Molecular Biology.

[17]  J. Gabrilove,et al.  A Phase I Trial of the Epigenetic Modulators Vorinostat, in Combination with Azacitidine (azaC) in Patients with the Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML): A Study of the New York Cancer Consortium , 2008 .

[18]  M. Bitzer,et al.  Inhibition of the TGF-beta receptor I kinase promotes hematopoiesis in MDS. , 2008, Blood.

[19]  Quan Chen,et al.  An analytical pipeline for genomic representations used for cytosine methylation studies , 2008, Bioinform..

[20]  K. Anderson,et al.  The molecular signature of MDS stem cells supports a stem-cell origin of 5q myelodysplastic syndromes. , 2007, Blood.

[21]  R. Verhaak,et al.  A distal single nucleotide polymorphism alters long-range regulation of the PU.1 gene in acute myeloid leukemia. , 2007, The Journal of clinical investigation.

[22]  W. Guida,et al.  Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity , 2007, Proceedings of the National Academy of Sciences.

[23]  A. Verma,et al.  From bloodjournal.hematologylibrary.org at PENN STATE UNIVERSITY on February 21, 2013. For personal use only. , 2005 .

[24]  Christian Steidl,et al.  Essential role of Jun family transcription factors in PU.1 knockdown–induced leukemic stem cells , 2006, Nature Genetics.

[25]  Bianca Sperl,et al.  Stattic: a small-molecule inhibitor of STAT3 activation and dimerization. , 2006, Chemistry & biology.

[26]  T. Golub,et al.  Transformation from committed progenitor to leukaemia stem cell initiated by MLL–AF9 , 2006, Nature.

[27]  Kenny Q. Ye,et al.  Comparative isoschizomer profiling of cytosine methylation: the HELP assay. , 2006, Genome research.

[28]  B. Cheson,et al.  Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. , 2006, Blood.

[29]  I. Weissman,et al.  The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[30]  Laurie E Ailles,et al.  Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. , 2004, The New England journal of medicine.

[31]  E. Fikrig,et al.  STAT3 deletion during hematopoiesis causes Crohn's disease-like pathogenesis and lethality: A critical role of STAT3 in innate immunity , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[32]  Irving L. Weissman,et al.  Prospective isolation of human clonogenic common myeloid progenitors , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[33]  R. DePinho,et al.  STAT3 is a negative regulator of granulopoiesis but is not required for G-CSF-dependent differentiation. , 2002, Immunity.

[34]  S. E. Jacobsen,et al.  Isolation and characterization of hematopoietic progenitor/stem cells in 5q-deleted myelodysplastic syndromes: evidence for involvement at the hematopoietic stem cell level. , 2000, Blood.

[35]  T Hamblin,et al.  International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.